Reference - Detail
|Author||Cao S, Wang Z, Gao X, He W, Cai Y, Chen H, Xu R.|
|Title||FOXC1 induces cancer stem cell-like properties through upregulation of beta-catenin in NSCLC.|
|Journal||J Exp Clin Cancer Res|
BACKGROUND:Accumulating evidence suggests that cancer stem cells (CSCs) play a critical role in tumor initiation, progression and therapy, and recent studies have indicated that Forkhead box C1 (FOXC1) is strongly associated with CSCs. This study investigates the regulatory effects of FOXC1 on CSC-like properties in non-small cell lung cancer (NSCLC).
METHODS:We analyzed FOXC1 expression in NSCLC using the Cancer Genome Atlas (TCGA) database on UALCANC and performed survival analyses of NSCLC patients on Human Protein Atlas. CSC-like properties were analyzed based on CSC marker-positive cell population, self-renewal ability, stemness-related gene expression, tumorigenicity and drug resistance. The percentage of CD133+ cells was analyzed by flow cytometric analysis. Self-renewal ability was detected by sphere-formation analysis. Real-time PCR, western blotting and immunohistochemical staining were employed to detect mRNA and protein levels. Tumorigenicity was determined based on a xenograft formation assay, and effects of FOXC1 on drug resistance were assessed by cell viability and apoptosis assays. Luciferase reporter and chromatin immunoprecipitation (ChIP) assays were used to investigate the binding of FOXC1 to beta-catenin promoter.
RESULTS:FOXC1 expression was found to be elevated in NSCLC tissues and negatively correlated with patient survival. FOXC1 knockdown reduced CD133+ cell percentage, suppressed self-renewal ability, decreased expression of stemness-related genes (Oct4, NANOG, SOX2 and ABCG2) and inhibited NSCLC cell tumorigenicity in vivo. Moreover, FOXC1 knockdown increased cisplatin and docetaxel sensitivity and reduced gefitinib resistance, whereas FOXC1 overexpression enhanced CSC-like properties. Luciferase reporter and ChIP assays showed beta-catenin to be a direct transcriptional target of FOXC1. Furthermore, overexpression of beta-catenin reversed the CSC-like property inhibition induced by FOXC1 knockdown, and knockdown of beta-catenin attenuated the CSC-like properties induced by FOXC1 overexpression.
CONCLUSIONS:This study demonstrates that FOXC1 induces CSC-like properties in NSCLC by promoting beta-catenin expression. The findings indicate that FOXC1 is a potential molecular target for anti-CSC-based therapies in NSCLC.
|MeSH||Apoptosis / genetics Carcinoma, Non-Small-Cell Lung / drug therapy Carcinoma, Non-Small-Cell Lung / genetics* Carcinoma, Non-Small-Cell Lung / pathology Cell Line, Tumor Cell Movement / genetics Cell Proliferation / genetics Cell Self Renewal / genetics* Cisplatin / pharmacology Docetaxel Drug Resistance, Neoplasm / genetics Forkhead Transcription Factors / genetics* Gene Expression Regulation, Neoplastic / genetics Gene Knockdown Techniques Humans Neoplastic Stem Cells / metabolism Neoplastic Stem Cells / pathology Taxoids / pharmacology beta Catenin / genetics*|
|Human and Animal Cells||PC-9(RCB4455)|